I-Mab (IMAB) Shows 83% Response Rate for Givastomig in Metastatic Gastric Cancer

Core Insights - I-Mab is recognized as one of the 15 best biotech penny stocks to invest in currently [1] - The company focuses on precision immuno-oncology, developing therapies specifically for cancer treatment [2] Company Overview - I-Mab (NASDAQ:IMAB) is a U.S.-based biotechnology firm specializing in precision immuno-oncology [2] - The lead candidate, givastomig, is a bispecific antibody targeting Claudin 18.2 and 4-1BB, aimed at selectively activating T cells in the tumor microenvironment [2] Clinical Progress - Positive Phase 1b dose escalation results for givastomig in combination with immunochemotherapy for first-line metastatic gastric cancer were presented at the ESMO GI 2025 conference [4] - The data showed an impressive 83% objective response rate at doses selected for expansion [4] - Enrollment in the Phase 1b expansion cohorts was completed ahead of schedule, with topline results expected in Q1 2026 [4] Financial Position - In August 2025, I-Mab raised approximately $61.2 million through an underwritten offering, increasing its pro-forma cash balance to $226.8 million as of June 30, 2025 [5] - This strong capital position is projected to fund operations through late 2028, supporting ongoing clinical development and pipeline advancement [5] Investor Engagement - In September 2025, I-Mab participated in major investor conferences, including the Cantor Global Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference, showcasing its strategic vision and pipeline progress [3]